Mydriacyl (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body muscles. This antagonism prevents parasympathetic stimulation, causing the iris sphincter to relax (pupil dilation) and the ciliary muscle to become inactive (loss of accommodation).

The prescribed dose of Mydriacyl is determined by the treating eye specialist. Typically, one or two drops are instilled in the affected eye(s) as directed, with the timing and frequency adjusted to the specific diagnostic or therapeutic need.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks before prescribing Mydriacyl to pregnant or nursing individuals.

To request Mydriacyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with agents such as phenylephrine or cyclopentolate, tropicamide has a rapid onset and relatively short duration of action, making it suitable for routine diagnostic dilation. It is less likely to cause prolonged cycloplegia than cyclopentolate, while providing effective mydriasis similar to phenylephrine.

Mydriacyl should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light, and ensure the cap is tightly closed to maintain sterility and potency.

Mydriacyl is applied topically to the eye as an ophthalmic solution. The prescribed number of drops is placed into the conjunctival sac of the target eye(s) using a sterile dropper, following the clinician’s instructions regarding timing and any required repeat dosing.

The most serious adverse events include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and a significant rise in intra‑ocular pressure. Patients should be monitored for symptoms like severe eye pain, vision loss, or systemic allergic signs, and treatment should be stopped immediately if they occur.

Mydriacyl is contraindicated in individuals with known hypersensitivity to tropicamide or other anticholinergic agents, and it should be avoided in patients with narrow‑angle or uncontrolled glaucoma, as it may precipitate an acute attack.